CD19/CD22/BCMA CAR-T cell therapy

· Shanghai Cell Therapy Group Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CD19/CD22/BCMA CAR-T cell therapy, covering 2024-12-13 to 2024-12-13. Get the full timeline:

Most recent: Clinical Trial Update: A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma [EARLY_Phase 1]